Ir para o conteúdo principal

United States News Todas as matérias

Todas as matérias desta seção, das mais recentes às mais antigas — página 180 de 371.

Grafa
Technology

Sypris Solutions net loss deepens on supply chain disruptions and auto slowdown

Sypris Solutions (NASDAQ:SYPR) reported lower first-quarter revenue and a widening net loss, hit by a broader downturn in the commercial vehicle market and persistent component supply shortages that disrupted its electronics manufacturing operations.

Leia mais: Sypris Solutions net loss deepens on supply chain disruptions and auto slowdown
Grafa
Technology

Eltek slides into loss as currency pressures and regional conflict disrupted shipments

Eltek (NASDAQ:ELTK) reported a first-quarter net loss and lower revenue, as a combination of foreign currency headwinds, local security challenges, and logistical bottlenecks delayed the execution of its primary manufacturing backlog.

Leia mais: Eltek slides into loss as currency pressures and regional conflict disrupted shipments
Grafa
Technology

Ceragon beats estimates on India, North America infrastructure strength

Ceragon Networks (NASDAQ:CRNT) reported first-quarter revenue that surpassed analyst expectations, driven by resilient deployments of its millimeter-wave backhaul solutions across India and North America despite a slight year-over-year contraction in total sales.

Leia mais: Ceragon beats estimates on India, North America infrastructure strength
Grafa
Auto and cars

Driven Brands delivers strong profit amid footprint expansion and ad revenue growth

Driven Brands Holdings (NASDAQ:DRVN) reported a significant turnaround in its fourth-quarter bottom-line results, shaking off a prior-year net loss to deliver stable adjusted earnings supported by an expanded global automotive services retail footprint.

Leia mais: Driven Brands delivers strong profit amid footprint expansion and ad revenue growth
Grafa

BioLineRx, Hemispherian disclose promising data for glioblastoma candidate

BioLineRx (NASDAQ:BLRX) and Hemispherian AS announced encouraging preclinical data for their oncology candidate GLIX1, showcasing the experimental drug’s potential to combat glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer.

Leia mais: BioLineRx, Hemispherian disclose promising data for glioblastoma candidate